4//SEC Filing
Section 32 Fund 2, LP 4
Accession 0001104659-19-041303
CIK 0001680581other
Filed
Jul 21, 8:00 PM ET
Accepted
Jul 22, 4:30 PM ET
Size
10.7 KB
Accession
0001104659-19-041303
Insider Transaction Report
Form 4
Maris William J
10% Owner
Transactions
- Conversion
Common Stock
2019-07-22+464,285→ 464,285 total - Conversion
Series B Preferred Stock
2019-07-22−3,250,000→ 0 total→ Common Stock (464,285 underlying)
Section 32 GP 2, LLC
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2019-07-22−3,250,000→ 0 total→ Common Stock (464,285 underlying) - Conversion
Common Stock
2019-07-22+464,285→ 464,285 total
Section 32 Fund 2, LP
10% Owner
Transactions
- Conversion
Common Stock
2019-07-22+464,285→ 464,285 total - Conversion
Series B Preferred Stock
2019-07-22−3,250,000→ 0 total→ Common Stock (464,285 underlying)
Footnotes (2)
- [F1]On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein.
Documents
Issuer
Fulcrum Therapeutics, Inc.
CIK 0001680581
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001725306
Filing Metadata
- Form type
- 4
- Filed
- Jul 21, 8:00 PM ET
- Accepted
- Jul 22, 4:30 PM ET
- Size
- 10.7 KB